Consistent with the literature [18, 32, 33], we observed that AML1-ETO affected signaling, metabolic and hematopoietic specific pathways, processes that are often found to be deregulated in AML [34–36]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.